Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including complex robotic surgery, clinical trials and novel therapeutics such as precision medicine, CAR T-Cell Therapy and other forms of immunotherapy.
$1.2 Million Awarded to Rutgers Cancer Institute Director for Neuroendocrine Tumor Research
Steve K. Libutti, MD, FACS, was awarded a $1.2 million‘Petersen Accelerator Award’ from the Neuroendocrine Tumor Research Foundation (NETRF) to pursue work leading to precise treatments for neuroendocrine tumors – an uncommon cancer impacting an estimated 171,000 Americans. The award to Dr. Libutti, who is also senior vice president of oncology services for RWJBarnabas Health, will support investigation into a novel immune regulator called B7x to determine whether it has a role in shutting off the body’s immune response to fight against pancreatic neuroendocrine tumors. Learn more
Exploring New Treatment for Advanced Lung Cancer
Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer. The work, stemming from a multi-center phase 1 clinical trial led by Rutgers Cancer Institute, is published in the February 20 edition of JAMA Oncology (DOI:10.1001/jamaoncol. 2019.6731). Rutgers Cancer Institute radiation oncologist Salma Jabbour, MD, professor of radiation oncology at Rutgers Robert Wood Johnson Medical School, is the lead and corresponding author. Learn more
Saluting Our Social Workers
During this National Social Work Month, Rutgers Cancer Institute of New Jersey honors its dedicated team of oncology social workers. These compassionate and caring professionals help patients and their families effectively cope with the logistical and emotional challenges of cancer and have extensive experience in helping individuals navigate their cancer journey. Learn more
March is Colorectal Cancer Awareness Month
Colorectal cancer is the third most common type of cancer in both men and women and is the second leading cause of cancer death after lung cancer, according to the American Cancer Society. Many colorectal cancers can be prevented through regular screening. Screening can find precancerous polyps — abnormal growths in the colon or rectum — so that they can be removed before they turn into cancer. Rutgers Cancer Institute of New Jersey and ScreenNJ have numerous resources available that address screening and prevention. Visit our Resource Center
In the Pink!
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health partnered at the Annual ‘Play4Kay’ Rutgers Women's Basketball Pink Out Game recently to honor breast cancer survivors and caregivers. During the game, survivors served as honorary coaches and healthcare professionals were recognized for their role in the cancer fight during a special half-time presentation. See how we celebrated
